FR2971257B1 - COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF A RESPONSE OR NON-RESPONSE TO ANTI-HCV TREATMENT - Google Patents

COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF A RESPONSE OR NON-RESPONSE TO ANTI-HCV TREATMENT Download PDF

Info

Publication number
FR2971257B1
FR2971257B1 FR1151028A FR1151028A FR2971257B1 FR 2971257 B1 FR2971257 B1 FR 2971257B1 FR 1151028 A FR1151028 A FR 1151028A FR 1151028 A FR1151028 A FR 1151028A FR 2971257 B1 FR2971257 B1 FR 2971257B1
Authority
FR
France
Prior art keywords
response
hcv treatment
biomarkers
prognosis
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1151028A
Other languages
French (fr)
Other versions
FR2971257A1 (en
Inventor
Tarik Asselah
Benedicte Watelet
Ivan Bieche
Isabelle Catherine Batxelli
Nadine Lambert
Eve Laure Mathieu
Nathalie Jullian
Michel Vidaud
Patrick Marcellin
Mohammad Afshar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Ariana Pharmaceuticals SA
Bio Rad Innovations SAS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Ariana Pharmaceuticals SA
Bio Rad Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Ariana Pharmaceuticals SA, Bio Rad Pasteur SA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1151028A priority Critical patent/FR2971257B1/en
Priority to PCT/EP2012/052232 priority patent/WO2012107529A1/en
Priority to AU2012215436A priority patent/AU2012215436B2/en
Publication of FR2971257A1 publication Critical patent/FR2971257A1/en
Application granted granted Critical
Publication of FR2971257B1 publication Critical patent/FR2971257B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La demande est relative à des moyens permettant de pronostiquer si un sujet infecté par un ou des VHC a une forte probabilité de répondre à un traitement anti-VHC qui comprendra l'administration d'interféron et de ribavirine, ou si, au contraire, ce sujet a une forte probabilité de ne pas répondre à ce traitement anti-VHC. Les moyens de l'invention mettent notamment en œuvre le dosage des niveaux d'expression de gènes choisis, lesdits gènes choisis étant : - au moins deux gènes parmi HERC5, IL8, STAT2 ; et - au moins un gène parmi CCL21, CLDN1, CXCL6, FOXO1, G1P2, G1P3, IFI27, IFI35, IFI44, IFIT1, IFIT4, IFITM1, ITGA2, LGALS3BP, MDK, MX1, OAS1, OAS2, OAS3, OCLN, PLSCR1, RSAD2, STAT1, STMN2, USP18.The request relates to means making it possible to predict whether a subject infected with one or more HCVs has a high probability of responding to anti-HCV treatment which will include the administration of interferon and ribavirin, or whether, on the contrary, this subject has a high probability of not responding to this anti-HCV treatment. The means of the invention implement in particular the assaying of the levels of expression of selected genes, said selected genes being: at least two genes from among HERC5, IL8, STAT2; and - at least one gene from CCL21, CLDN1, CXCL6, FOXO1, G1P2, G1P3, IFI27, IFI35, IFI44, IFIT1, IFIT4, IFITM1, ITGA2, LGALS3BP, MDK, MX1, OAS1, OAS2, OAS3, OCLN, PL2SCR1, , STAT1, STMN2, USP18.

FR1151028A 2011-02-09 2011-02-09 COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF A RESPONSE OR NON-RESPONSE TO ANTI-HCV TREATMENT Active FR2971257B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR1151028A FR2971257B1 (en) 2011-02-09 2011-02-09 COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF A RESPONSE OR NON-RESPONSE TO ANTI-HCV TREATMENT
PCT/EP2012/052232 WO2012107529A1 (en) 2011-02-09 2012-02-09 Combination of biomarkers for forecasting a response or non-response to an anti-hcv treatment
AU2012215436A AU2012215436B2 (en) 2011-02-09 2012-02-09 Combination of biomarkers for forecasting a response or non-response to an anti-HCV treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1151028A FR2971257B1 (en) 2011-02-09 2011-02-09 COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF A RESPONSE OR NON-RESPONSE TO ANTI-HCV TREATMENT

Publications (2)

Publication Number Publication Date
FR2971257A1 FR2971257A1 (en) 2012-08-10
FR2971257B1 true FR2971257B1 (en) 2020-12-04

Family

ID=44992978

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1151028A Active FR2971257B1 (en) 2011-02-09 2011-02-09 COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF A RESPONSE OR NON-RESPONSE TO ANTI-HCV TREATMENT

Country Status (3)

Country Link
AU (1) AU2012215436B2 (en)
FR (1) FR2971257B1 (en)
WO (1) WO2012107529A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA2257109C (en) 1996-06-04 2009-10-06 University Of Utah Research Foundation Monitoring hybridization during pcr
EP1953242A1 (en) * 2007-02-05 2008-08-06 INSERM (Institut National de la Santé et de la Recherche Medicale) Methods and kits for determining drug sensitivity in patientsinfected with HCV
WO2010076788A2 (en) * 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection

Also Published As

Publication number Publication date
AU2012215436A1 (en) 2013-05-02
WO2012107529A1 (en) 2012-08-16
AU2012215436B2 (en) 2015-07-09
FR2971257A1 (en) 2012-08-10

Similar Documents

Publication Publication Date Title
Beinhardt et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection
RU2008146518A (en) BIOMARKERS OF INFECTION Caused by the Hepatitis C Virus
Menicucci et al. Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
Fang et al. Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus
WO2019051257A3 (en) Methods for treating hepatitis b infections
EP2808402A3 (en) Methods of predicting responsiveness to interferon treatment
Gilbert et al. Age-related expression of IFN-λ1 versus IFN-I and beta-defensins in the nasopharynx of SARS-CoV-2-infected individuals
Brahim et al. Morocco underwent a drift of circulating hepatitis C virus subtypes in recent decades
Saxena et al. Interleukin-1 polymorphism and expression in hepatitis B virus-mediated disease outcome in India
Sadeghi et al. Associations between human TRIM22 gene expression and the response to combination therapy with Peg‐IFNα‐2a and ribavirin in Iranian patients with chronic hepatitis C
Mao et al. Virologic and immunologic characteristics in mature ducks with acute duck hepatitis A virus 1 infection
Younossi et al. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon‐alfa and ribavirin
He et al. Differential transcriptional responses to interferon-α and interferon-γ in primary human hepatocytes
FR2971259B1 (en) COMBINATION OF BIOMARKERS FOR PROGNOSIS OF RESPONSE OR NON-RESPONSE TO ANTI-HCV TREATMENT
Elaldi et al. Relationship between IFNA1, IFNA5, IFNA10, and IFNA17 gene polymorphisms and Crimean‐Congo hemorrhagic fever prognosis in a Turkish population range
FR2971257B1 (en) COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF A RESPONSE OR NON-RESPONSE TO ANTI-HCV TREATMENT
Imran et al. Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan
Barkhash et al. Association between polymorphisms in OAS2 and CD209 genes and predisposition to chronic hepatitis C in Russian population
Bordignon et al. Expression profile of interferon stimulated genes in central nervous system of mice infected with dengue virus Type-1
He et al. Long-term outcomes after nucleos (t) ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients
Lee et al. Pre‐existing YMDD mutants in treatment‐naïve patients with chronic hepatitis B are not selected during lamivudine therapy
JP2020065488A5 (en)
Rallon et al. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients
JP2017521654A5 (en)

Legal Events

Date Code Title Description
CD Change of name or company name

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20120813

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR

Effective date: 20120813

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FR

Effective date: 20120813

Owner name: ARIANA PHARMACEUTICALS, FR

Effective date: 20120813

Owner name: BIO RAD INNOVATIONS, FR

Effective date: 20120813

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13